A protective immune system cell disappears from a key form of fat, but only in those who are obese
The mammalian immune system is an evolutionary wonder. It's capable of recognizing and destroying cancer cells, and it can ...
AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025
CD3 T-cell engagers have the potential to be a cornerstone of cancer treatment. They guide the immune system to find and ...
If bird flu jumps to humans, immunity from seasonal flu may offer some protection
Very few humans have gone up against bird flu. But we've all dealt with seasonal flu for years. Some of our immune systems ...
Labroots7d
Immune Cell Mechanism Improves Antibody Production
Our immune system works to fight infections immediately, but also maintain long-term immunity. Two waves of protection help ...
The Manila Times2d
Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting
Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an ...
CURE16h
Quadruplet Regimen Preferable to Triplets in Multiple Myeloma
Dr. Cesar Rodriguez discussed treatment advancements for multiple myeloma during a CURE Educated Patient® Summit.
Fierce Biotech3d
Speed, Scale, and Success – The Rise of Bispecific Antibodies in Targeted Therapies
Bispecific antibodies (BsAbs) have emerged as a transformative class of biologics, offering dual-targeting mechanisms that enhance therapeutic efficacy across oncology, autoimmune disorders, and ra | ...
Morningstar2d
Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting
our DLL3-targeting trispecific T cell engager incorporating co-stimulation, which is on track for IND submission in 1H-2026, and ZW327, our Ly6E-targeting antibody-drug conjugate incorporating our ...
Finanznachrichten2d
Zymeworks Inc.: Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting
Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile New antibody-drug conjugate (ADC) candidate ...